Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 35

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 35
---
 or sale of the offered
securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent
will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.

We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect
to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.

Delayed Delivery Contracts

If the prospectus supplement
indicates, we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities
at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date
in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus
supplement will describe the commission payable for solicitation of those contracts.

Continuous Offering Program

Without limiting the generality
of the foregoing, we may enter into a continuous offering program equity distribution agreement with a broker-dealer, under which we may
offer and sell shares of our common stock from time to time through a broker-dealer as our sales agent. If we enter into such a program,
sales of the shares of common stock, if any, will be made by means of ordinary brokers’ transactions on the NASDAQ Capital Market
at market prices, block transactions and such other transactions as agreed upon by us and the broker-dealer. Under the terms of such a
program, we also may sell shares of common stock to the broker-dealer, as principal for its own account at a price agreed upon at the
time of sale. If we sell shares of common stock to such broker-dealer as principal, we will enter into a separate terms agreement with
such broker-dealer, and we will describe this agreement in a separate prospectus supplement or pricing supplement.

<div align='center'>11</div>

Market Making, Stabilization and Other Transactions

Unless the applicable prospectus
supplement states otherwise, other than our common stock all securities we offer under this prospectus will be a new issue and will have
no established trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters
that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time
without notice. Therefore, we